Pfizer To Pay Nearly $60 Million To Resolve Kickback Allegations

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Pfizer To Pay Nearly $60 Million To Resolve Kickback Allegations Arising From Subsidiary’s Speaker Programs

Dennis Tosh

January 29, 2025 at 06:59 PM EST

Pfizer Inc. has agreed to pay nearly $60 million to the federal government and state Medicaid programs to resolve allegations that a subsidiary’s speaker programs caused the submission of false reimbursement claims to federal health care programs (United States ex rel. Frattasio v. Biohaven Pharmaceutical Holding Co. Ltd., No. 6:21-cv-06539-CJS (W.D.N.Y.)). Before being acqui... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Pfizer To Pay Nearly $60 Million To Resolve Kickback Allegations Arising From Subsidiary’s Speaker Programs

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT